159 related articles for article (PubMed ID: 35140049)
1. Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma.
Rosiello G; Larcher A; Fallara G; Giancristofaro C; Martini A; Re C; Cei F; Musso G; Tian Z; Karakiewicz PI; Mottrie A; Bertini R; Salonia A; Necchi A; Raggi D; Briganti A; Montorsi F; Capitanio U
Urol Oncol; 2022 Jun; 40(6):271.e19-271.e27. PubMed ID: 35140049
[TBL] [Abstract][Full Text] [Related]
2. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
[TBL] [Abstract][Full Text] [Related]
3. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.
Klatte T; Gallagher KM; Afferi L; Volpe A; Kroeger N; Ribback S; McNeill A; Riddick ACP; Armitage JN; 'Aho TF; Eisen T; Fife K; Bex A; Pantuck AJ; Stewart GD
BMC Med; 2019 Oct; 17(1):182. PubMed ID: 31578141
[TBL] [Abstract][Full Text] [Related]
4. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
5. Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation.
Nocera L; Collà Ruvolo C; Stolzenbach LF; Wenzel M; Tian Z; Larcher A; Capitanio U; Mirone V; Tilki D; Chun FKH; Kapoor A; Shariat SF; Saad F; Montorsi F; Briganti A; Karakiewicz PI
Eur Urol Focus; 2022 Jan; 8(1):182-190. PubMed ID: 33653677
[TBL] [Abstract][Full Text] [Related]
6. Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients.
Piccinelli ML; Barletta F; Tappero S; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Luzzago S; Mistretta FA; Ferro M; Saad F; Shariat SF; Ahyai S; Longo N; Tilki D; Chun FKH; Terrone C; Briganti A; de Cobelli O; Musi G; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):799-806. PubMed ID: 37024421
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.
Tan MH; Kanesvaran R; Li H; Tan HL; Tan PH; Wong CF; Chia KS; Teh BT; Yuen J; Chong TW
Urology; 2010 Jun; 75(6):1365-1370; 1370.e1-3. PubMed ID: 20022084
[TBL] [Abstract][Full Text] [Related]
8. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
Oza B; Eisen T; Frangou E; Stewart GD; Bex A; Ritchie AWS; Kaplan R; Smith B; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Joniau S; Hancock B; Hermann GG; Bellmunt J; Parmar MKB; Royston P; Meade A
J Clin Oncol; 2022 Jun; 40(16):1772-1782. PubMed ID: 35213214
[TBL] [Abstract][Full Text] [Related]
9. External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: A multi-institutional analysis.
Erdem S; Capitanio U; Campi R; Mir MC; Roussel E; Pavan N; Kara O; Klatte T; Kriegmair MC; Degirmenci E; Aydin R; Minervini A; Serni S; Berni A; Rebez G; Ozcan F;
Urol Oncol; 2022 May; 40(5):198.e9-198.e17. PubMed ID: 35172939
[TBL] [Abstract][Full Text] [Related]
10. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.
Beck SD; Patel MI; Snyder ME; Kattan MW; Motzer RJ; Reuter VE; Russo P
Ann Surg Oncol; 2004 Jan; 11(1):71-7. PubMed ID: 14699037
[TBL] [Abstract][Full Text] [Related]
11. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
[TBL] [Abstract][Full Text] [Related]
12. GRade, Age, Nodes, and Tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: A nationwide study.
Juul S; Donskov F; Clark PE; Lund L; Azawi NH
Int J Urol; 2022 Jul; 29(7):641-645. PubMed ID: 35362146
[TBL] [Abstract][Full Text] [Related]
13. 2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race.
Schmeusser BN; Patil DH; Nicaise EH; Armas-Phan M; Nabavizadeh R; Narayan VM; Joshi SS; Ogan K; Osunkoya AO; Bilen MA; Master VA
Cancer; 2024 Feb; 130(3):453-466. PubMed ID: 37803521
[TBL] [Abstract][Full Text] [Related]
14. Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma.
Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; Tian Z; Larcher A; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Urol Oncol; 2020 May; 38(5):537-544. PubMed ID: 32122729
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1-4 cm renal cell carcinomas.
Rosiello G; Pecoraro A; Luzzago S; Deuker M; Stolzenbach LF; Tian Z; Larcher A; Capitanio U; Montorsi F; Shariat SF; Kapoor A; Saad F; Briganti A; Karakiewicz PI
Cancer Causes Control; 2021 Feb; 32(2):119-126. PubMed ID: 33169306
[TBL] [Abstract][Full Text] [Related]
16. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study.
Capitanio U; Cloutier V; Zini L; Isbarn H; Jeldres C; Shariat SF; Perrotte P; Antebi E; Patard JJ; Montorsi F; Karakiewicz PI
BJU Int; 2009 Jun; 103(11):1496-500. PubMed ID: 19076149
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract][Full Text] [Related]
18. Predicting recurrence and survival in patients with non-metastatic renal-cell carcinoma after nephrectomy: a prospective population-based study with multicenter validation.
Wang Y; Xuan Y; Su B; Gao Y; Fan Y; Huang Q; Zhang P; Gu L; Niu S; Shen D; Li X; Wang B; Zhu Q; Ouyang Z; Xie J; Ma X
Int J Surg; 2024 Feb; 110(2):820-831. PubMed ID: 38016139
[TBL] [Abstract][Full Text] [Related]
19. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma.
Cheville JC; Lohse CM; Zincke H; Weaver AL; Blute ML
Am J Surg Pathol; 2003 May; 27(5):612-24. PubMed ID: 12717246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
